The selective M1 muscarinic cholinergic agonist CDD-0102A enhances working memory and cognitive flexibility.

Michael E Ragozzino, Sonja Artis, Amritha Singh, Trevor M Twose, Joseph E Beck, William S Messer

Department of Psychology, Laboratory of Integrative Neuroscience, University of Illinois at Chicago, Chicago, Illinois, USA.

The Journal of pharmacology and experimental therapeutics 2012 Mar

filter terms:

Various neurodegenerative diseases and psychiatric disorders are marked by alterations in brain cholinergic function and cognitive deficits. Efforts to alleviate such deficits have been limited by a lack of selective M(1) muscarinic agonists. 5-(3-Ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride (CDD-0102A) is a partial agonist at M(1) muscarinic receptors with limited activity at other muscarinic receptor subtypes. The present studies investigated the effects of CDD-0102A on working memory and strategy shifting in rats. CDD-0102A administered intraperitoneally 30 min before testing at 0.1, 0.3, and 1 mg/kg significantly enhanced delayed spontaneous alternation performance in a four-arm cross maze, suggesting improvement in working memory. In separate experiments, CDD-0102A had potent enhancing effects on learning and switching between a place and visual cue discrimination. Treatment with CDD-0102A did not affect acquisition of either a place or visual cue discrimination. In contrast, CDD-0102A at 0.03 and 0.1 mg/kg significantly enhanced a shift between a place and visual cue discrimination. Analysis of the errors in the shift to the place or shift to the visual cue strategy revealed that in both cases CDD-0102A significantly increased the ability to initially inhibit a previously relevant strategy and maintain a new, relevant strategy once selected. In anesthetized rats, the minimum dose required to induce salivation was approximately 0.3 mg/kg i.p. Salivation increased with dose, and the estimated ED(50) was 2.0 mg/kg. The data suggest that CDD-0102A has unique memory and cognitive enhancing properties that might be useful in the treatment of neurological disorders at doses that do not produce adverse effects such as salivation.

Citation

Michael E Ragozzino, Sonja Artis, Amritha Singh, Trevor M Twose, Joseph E Beck, William S Messer. The selective M1 muscarinic cholinergic agonist CDD-0102A enhances working memory and cognitive flexibility. The Journal of pharmacology and experimental therapeutics. 2012 Mar;340(3):588-94